Skip to content

The Effectiveness of Smartphone-Based Speech Therapy for People with Post-Stroke Dysarthria

A Prospective, Randomized, Multi-Centered Clinical Trial to Investigate the Effectiveness of Smartphone-Based Speech Therapy for People with Post-Stroke Dysarthria

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05877950
Enrollment
100
Registered
2023-05-26
Start date
2024-09-30
Completion date
2025-12-31
Last updated
2024-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysarthria As Late Effect of Stroke

Brief summary

This clinical trial aims to determine if a new smartphone-based speech therapy is effective self-treatment method for patients with post-stroke dysarthria. For this study, participants in the intervention group will use the speech therapy app for 1 hour per day, 5 days per week, over a 4-week period. The active control group will receive home-based speech therapy with the same duration and frequency as the intervention group. The study will help us understand if smartphone-based speech therapy is a viable treatment option for post-stroke dysarthria patients.

Detailed description

In this study, 100 patients with post-stroke dysarthria will be recruited and stratified into acute-subacute (within 1 month after index stroke) and chronic (after 6 months after index stroke) groups. Participants will then be randomly assigned to either the intervention or active control group. Patients in the intervention group will use a smartphone-based speech therapy app that includes oro-motor exercise, phonation, articulation, resonance, syllable repetition, and reading exercises. Treatment goals and contents will be determined based on individual patient conditions by a speech-language pathologist after the baseline evaluation. Participants will receive daily sessions for 1 hour per day, 5 days per week, over a 4-week period. Patients in the active control group will receive home-based speech therapy, which includes oro-motor exercises and reading tasks from a workbook, for the same frequency as the intervention group. Both groups will also receive usual stroke care. The study aims to evaluate the efficacy of mobile-based speech therapy compared to home-based speech therapy in improving speech intelligibility scores 4 weeks after baseline for patients with dysarthria in the acute-subacute and chronic phases following stroke.

Interventions

Participants will be instructed to use the speech therapy app for 1 hour per day (5 days for 1 week) over a 4-week period.

OTHERHome-based speech therapy

Participants will receive treatment maintaining the same frequency as the intervention group.

Sponsors

Ewha Womans University Mokdong Hospital
CollaboratorOTHER
National Rehabilitation Center, Seoul, Korea
CollaboratorOTHER_GOV
Ewha Womans University Seoul Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Aged 18 or over. 2. Neurologically stable stroke patients diagnosed by a stroke specialist neurologist. 3. Diagnosis of dysarthria caused by stroke as confirmed by a stroke specialty neurologist. 4. First-ever stroke patients without previous stroke history. 5. Patients with sufficient cognitive abilities to operate the smartphone-based speech therapy application (Mini-Mental State Exam score ≥ 26) 6. As judged by the neurology specialists: patients with sufficient vision, hearing, communication skills, and motor skills to participate in this study 7. Must have voluntarily understood the trial and signed a consent form agreeing to comply with precautions.

Exclusion criteria

1. Co-existing language disorder (e.g., aphasia). Aphasia will be determined by a stroke specialist. 2. Co-existing progressive neurological disorders that can affect dysarthria (e.g., dementia, Pick's disease, Huntington's disease, Parkinson's disease, or Parkinsonism). 3. Diagnosis of severe mental disorders as determined by a clinician (e.g., depression, schizophrenia, alcohol addiction, or drug addiction). 4. Patients taking concomitant medications that could affect the trial results during the study period (e.g., cognitive dysfunction medications, anticholinergics, anti-epileptic drugs, anti-anxiety drugs, antidepressants, antipsychotics, and hypnotics). 5. Patients unable to use/access smartphone technology. 6. Illiterate patients. 7. Patients unable to communicate in Korean. 8. Is unsuitable for participation due to other reasons, as determined by the investigator. 9. Has refused to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
Speech intelligibilityBaseline, 4 weeksThe change in speech intelligibility from baseline to 4 weeks post-intervention will be assessed. Speech intelligibility will be evaluated by having three naive listeners transcribe the participants' recorded speech. These transcriptions will then be compared to the original sentences to calculate a percentage score representing intelligibility. The final intelligibility score will be calculated as the average of the scores from the three naive listeners. A higher percentage indicates greater speech intelligibility.

Secondary

MeasureTime frameDescription
Maximum phonation Time (MPT)Baseline, 4 weeksThe change in maximum phonation time (MPT) from baseline to 4 weeks post-intervention will be assessed. MPT will be used to assess participants' maximum phonation time. The speech evaluator instructs the patient to take a comfortable breath and then produce the sound /a/ for as long as possible. The task is performed twice, and the maximum duration of the two measurements is used.
Oral-diadochokinesis (DDK)Baseline, 4 weeksThe Oral-diadochokinesis (DDK) change from baseline to 4 weeks post-intervention will be assessed. DDK will be used to assess articulation rate, regularity, and accuracy. Participants are instructed to repeat the syllables /pa/, /ta/, /ka/, and /pataka/ as quickly and accurately as possible. The number of repetitions is divided by the duration of the task.
Percentage of Consonants Correct (PCC, %)Baseline, 4 weeksThe Percentage of Consonants Correct (PCC, %) change from baseline to 4 weeks post-intervention will be assessed. PCC is evaluated as a percentage score calculated from the Urimal Test of Articulation and Phonology 2 (UTAP2).

Other

MeasureTime frameDescription
Patient Health Questionnaire-9 (PHQ-9)Baseline, 4 weeksPHQ-9 will be used to assess depression. The PHQ-9 is a nine-item self-reported questionnaire for the measurement of depressive symptoms during the last two weeks.
Application usage logs4 weeksThe log data will be used to evaluate compliance and acoustic factors. During the 4-week experimental period, the application login time, daily task completion rate, and raw data (.wav) of patients' voices are stored on the server for analysis.
Quality of Life in the Dysarthric Speaker (QOL-Dys)Baseline, 4 weeksQOL-Dys will be used to assess the comprehensive quality of life of individuals with dysarthria. The questionnaire consists of four dimensions: characteristics of speech, situational difficulties, use of compensation strategies, and perception of others. The responses are rated on a 5-point scale from 0 to 4, indicating the extent to which participants agree with each statement.
Communicative Effectiveness Survey (CES)Baseline, 4 weeksCES will be used to assess the communication efficiency of individuals with dysarthria in daily situations. The rating scale consists of 8 items and uses a 7-category rating scale ranging from 1 = not effective at all to 7 = extremely effective for everyday speaking situations.
System Usability Questionnaire (SUS)4 weeksSUS will be used to assess user's subjective views of a system's usability. SUS will only be used in the intervention group at the end of treatment.

Contacts

Primary ContactEwha Womans University Medical Center
knstar@hanmail.net+82-2-6986-3307

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026